To identify candidate therapeutic targets in T-ALL, we evaluated inhibitors of epigenetic modifiers, including modulators of the histone acetyltransferase (HAT) p300 (CTPB and C646) and inhibitors of protein methyltransferases (PMTs), small molecules targeting EZH2 (GSK126), DOT1L (SGC0946), and G9a (EHMT2)/G9a-like-(GLP) (EHMT1) (UNC0638 and BIX01294). This evidence concerns the gene EZH2 and acute lymphoblastic leukemia.